Table 5 |
|||||||||||
|
Interactions between nonsteroidal anti-inflammatory drug (NSAID) use and MDR1, COX-2 and BCRP polymorphisms. |
|||||||||||
|
Polymorphism |
Ncase/Nsub-cohort |
IRRa (95% CI) |
IRRb (95% CI) |
p-valuec |
|||||||
|
NSAIDd |
NSAIDd |
NSAIDd |
|||||||||
|
NO |
YES |
NO |
YES |
NO |
YES |
||||||
|
|
|||||||||||
|
MDR1 C3435T |
|||||||||||
|
CC |
41/79 |
32/39 |
1.00 |
- |
2.21 |
(1.17-4.17) |
1.00 |
- |
2.34 |
(1.22-4.48) |
0.001 |
|
CT and TT |
204/449 |
82/198 |
0.92 |
(0.60-1.41) |
0.83 |
(0.52-1.33) |
0.99 |
(0.63-1.54) |
0.86 |
(0.53-1.39) |
|
|
MDR1 G-rs 3789243-A |
|||||||||||
|
GG |
54/160 |
27/64 |
1.00 |
- |
1.35 |
(0.77-2.35) |
1.00 |
- |
1.31 |
(0.74-2.32) |
0.26 |
|
GA and AA |
191/368 |
87/173 |
1.65 |
(1.15-2.38) |
1.65 |
(1.09-2.49) |
1.66 |
(1.15-2.41) |
1.61 |
(1.06-2.46) |
|
|
COX-2 G-765C |
|||||||||||
|
GG |
180/397 |
87/169 |
1.00 |
- |
1.22 |
(0.89-1.69) |
1.00 |
- |
1.20 |
(0.86-1.67) |
0.06 |
|
CG and CC |
65/131 |
27/68 |
1.22 |
(0.86-1.75) |
0.93 |
(0.57-1.51) |
1.23 |
(0.85-1.78) |
0.90 |
(0.54-1.48) |
|
|
COX-2 A-1195G |
|||||||||||
|
AA |
156/329 |
74/153 |
1.00 |
- |
1.05 |
(0.75-1.48) |
1.00 |
- |
0.99 |
(0.69-1.41) |
0.46 |
|
AG and GG |
89/199 |
40/84 |
0.91 |
(0.66-1.27) |
1.04 |
(0.67-1.60) |
0.88 |
(0.63-1.23) |
1.04 |
(0.67-1.61) |
|
|
COX-2 T8473C |
|||||||||||
|
TT |
94/222 |
53/93 |
1.00 |
- |
1.42 |
(0.92-2.18) |
1.00 |
- |
1.38 |
(0.89-2.14) |
0.04 |
|
CT and CC |
151/306 |
61/144 |
1.23 |
(0.89-1.70) |
1.09 |
(0.73-1.62) |
1.22 |
(0.87-1.69) |
1.05 |
(0.70-1.58) |
|
|
BCRP C421A |
|||||||||||
|
CC |
199/414 |
97/178 |
1.00 |
- |
1.20 |
(0.88-1.63) |
1.00 |
- |
1.18 |
(0.85-1.62) |
0.09 |
|
CA and AA |
46/114 |
17/59 |
0.86 |
(0.58-1.27) |
0.62 |
(0.35-1.10) |
0.86 |
(0.57-1.29) |
0.60 |
(0.33-1.08) |
|
|
|
|||||||||||
|
aCrude (adjusted for age and sex). bAdjusted for status of HRT (women only), smoking status, alcohol, dietary fibre, red meat and BMI. cp-value for interaction for the fully adjusted risk estimates. dStudy subjects were classified according to use of "any NSAID" (≥ 2 pills per month during one year) at baseline |
|||||||||||
|
Andersen et al. BMC Cancer 2009 9:407 doi:10.1186/1471-2407-9-407 |
|||||||||||
